BR112014000713A2 - derivados de indol substituído como moduladores de gama secretase - Google Patents

derivados de indol substituído como moduladores de gama secretase

Info

Publication number
BR112014000713A2
BR112014000713A2 BR112014000713A BR112014000713A BR112014000713A2 BR 112014000713 A2 BR112014000713 A2 BR 112014000713A2 BR 112014000713 A BR112014000713 A BR 112014000713A BR 112014000713 A BR112014000713 A BR 112014000713A BR 112014000713 A2 BR112014000713 A2 BR 112014000713A2
Authority
BR
Brazil
Prior art keywords
compounds
indole derivatives
gamma secretase
substituted indole
secretase modulators
Prior art date
Application number
BR112014000713A
Other languages
English (en)
Inventor
Adriana Ingrid Velter
Didier Jean-Claude Berthelot
François Paul Bischoff
Garrett Berlond Minne
Henricus Jacobus Maria Gijsen
Serge Maria Aloysius Pieters
Original Assignee
Cellzome Ltd
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ltd, Janssen Pharmaceuticals Inc filed Critical Cellzome Ltd
Publication of BR112014000713A2 publication Critical patent/BR112014000713A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

abstract novel substituted indole derivatives as gamma secretase modulators ____________________________________________ the present invention is concerned with novel substituted indole derivatives of formula (i) wherein r1, r2, r3, a1, a2, a3, y and x have the meaning defined in the claims. the compounds according to the present invention are useful as gamma secretase modulators. the invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament. 129 ******************************************************* tradução do resumo resumo patente de invenção: "derivados de indol substituído como moduladores de gama secretase". a presente invenção refere-se a novos derivados de indol substituído de fórmula (i) em que r1, r2, r3, a1, a2, a3, y e x têm o significado definido nas reivindicações. os compostos de acordo com a presente invenção são úteis como moduladores de gama secretase. a invenção também se refere a processos para a preparação desses compostos novos, a composições farmacêuticas compreendendo os referidos compostos como ingrediente ativo, bem como à utilização dos referidos compostos como medicamento.
BR112014000713A 2011-07-15 2012-07-12 derivados de indol substituído como moduladores de gama secretase BR112014000713A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11174120 2011-07-15
PCT/EP2012/063667 WO2013010904A1 (en) 2011-07-15 2012-07-12 Novel substituted indole derivatives as gamma secretase modulators

Publications (1)

Publication Number Publication Date
BR112014000713A2 true BR112014000713A2 (pt) 2017-01-10

Family

ID=46506432

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000713A BR112014000713A2 (pt) 2011-07-15 2012-07-12 derivados de indol substituído como moduladores de gama secretase

Country Status (16)

Country Link
US (1) US9115143B2 (pt)
EP (1) EP2731948B1 (pt)
JP (1) JP6068464B2 (pt)
KR (1) KR101913135B1 (pt)
CN (1) CN103874702B (pt)
AR (1) AR087182A1 (pt)
AU (1) AU2012285931B2 (pt)
BR (1) BR112014000713A2 (pt)
CA (1) CA2841102C (pt)
EA (1) EA023045B1 (pt)
ES (1) ES2555167T3 (pt)
IL (1) IL230422B (pt)
IN (1) IN2014MN00258A (pt)
MX (1) MX2014000626A (pt)
TW (1) TWI567079B (pt)
WO (1) WO2013010904A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011008335A (es) 2009-02-06 2011-09-06 Ortho Mcneil Janssen Pharm Novedosos compuestos heterociclicos biciclicos sustituidos como moduladores de la gamma secretasa.
JP5559309B2 (ja) 2009-05-07 2014-07-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体
SG177644A1 (en) 2009-07-15 2012-03-29 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
US9079886B2 (en) 2010-01-15 2015-07-14 Janssen Pharmaceuticals, Inc. Substituted triazole derivatives as gamma secretase modulators
US8987276B2 (en) 2011-03-24 2015-03-24 Janssen Pharmaceuticals, Inc. Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
BR112014028395B1 (pt) 2012-05-16 2022-02-01 Janssen Pharmaceuticals, Inc. Derivados 3,4-di-hidro-2h-pirido[1,2-a]pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer e composição farmacêutica que os compreende
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
CN104918938B (zh) 2012-12-20 2017-08-15 詹森药业有限公司 新颖的作为γ分泌酶调节剂的三环3，4‑二氢‑2H‑吡啶并[1，2‑a]吡嗪‑1，6‑二酮衍生物
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2018026620A1 (en) 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
US10660877B2 (en) 2016-09-09 2020-05-26 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019028302A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
JP7266576B2 (ja) 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物
MA50356A (fr) * 2017-10-11 2021-04-21 Hoffmann La Roche Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1
ES2945435T3 (es) 2017-11-14 2023-07-03 Bristol Myers Squibb Co Compuestos de indol sustituidos
CN111819176B (zh) 2017-12-18 2023-12-15 百时美施贵宝公司 4-氮杂吲哚化合物
WO2019126082A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
US11420973B2 (en) 2017-12-19 2022-08-23 Bristol-Myers Squibb Company Amide substituted indole compounds useful as TLR inhibitors
KR20200101402A (ko) 2017-12-19 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 치환된 인돌 화합물
EA202091479A1 (ru) 2017-12-20 2020-11-24 Бристол-Маерс Сквибб Компани Арил- и гетероарилзамещенные индольные соединения
EA202091530A1 (ru) 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
CN111491929B (zh) 2017-12-20 2023-11-28 百时美施贵宝公司 可用作tlr抑制剂的氨基吲哚化合物
PE20210860A1 (es) * 2018-09-03 2021-05-18 Hoffmann La Roche Derivados de heteroarilo biciclicos
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
EP3870589B1 (en) 2018-10-24 2023-09-06 Bristol-Myers Squibb Company Substituted indole dimer compounds

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172975T1 (de) * 1992-05-19 1998-11-15 Adir Benzimidezolderivate mit antidiabetischer und anti-plättchenklumpungswirkung
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6114334A (en) 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
OA11958A (en) 1999-06-10 2006-04-13 Warner Lambert Co Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
EP1284729A4 (en) 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
DE10109867A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
RU2005129550A (ru) 2003-02-27 2006-07-27 Ф.Хоффманн-Ля Рош Аг (Ch) Антагонисты рецептора ccr-3
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
EP1656353B1 (en) 2003-08-14 2010-01-27 F. Hoffmann-La Roche Ag Gabanergic modulators
EP1725555B1 (en) 2004-03-08 2010-10-06 Prosidion Ltd. Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
US7880009B2 (en) 2004-05-26 2011-02-01 Eisai R&D Management Co., Ltd. Cinnamide compound
EP1808432B1 (en) 2004-10-26 2010-02-24 Eisai R&D Management Co., Ltd. Amorphous form of cinnamide compound
EP2457901A1 (en) * 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
JP2009508929A (ja) 2005-09-22 2009-03-05 サノフイ−アベンテイス Ｃｃｒ３受容体リガンドとしてのアミノ−アルキル−アミド誘導体
WO2007043786A1 (en) 2005-10-10 2007-04-19 Seiyang Yang Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same
EA200801063A1 (ru) 2005-10-11 2008-12-30 Кемтура Корпорейшн Диароматические амины
AR056785A1 (es) 2005-11-10 2007-10-24 Schering Corp COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
EP2099798A1 (en) 2006-12-01 2009-09-16 Galapagos N.V. Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
JP2010512390A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション 三環式系を含むアスパルチルプロテアーゼ阻害剤
JP2010513495A (ja) 2006-12-20 2010-04-30 シェーリング コーポレイション 新規なｊｎｋ阻害剤
EP2117311A4 (en) 2007-02-08 2011-05-11 Merck Sharp & Dohme THERAPEUTICS
WO2008099210A2 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2120573A4 (en) 2007-02-12 2011-05-25 Merck Sharp & Dohme DERIVATIVES OF PIPERIDINE
CN101809019A (zh) 2007-05-07 2010-08-18 先灵公司 γ分泌酶调节剂
EP2155740B1 (en) 2007-05-11 2011-01-26 F. Hoffmann-La Roche AG Hetarylanilines as modulators for amyloid beta
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
CN101772493A (zh) 2007-06-29 2010-07-07 先灵公司 γ分泌酶调节剂
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
EP2229381A1 (en) 2007-12-06 2010-09-22 Schering Corporation Gamma secretase modulators
CN101945868A (zh) 2007-12-11 2011-01-12 先灵公司 γ分泌酶调节剂
WO2009103652A1 (en) 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010045188A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
JP2012508182A (ja) 2008-11-06 2012-04-05 シェーリング コーポレイション γ−セクレターゼ調節剤
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
CN102239165A (zh) 2008-12-03 2011-11-09 维尔制药公司 二酰甘油酰基转移酶抑制剂
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
MX2011008335A (es) 2009-02-06 2011-09-06 Ortho Mcneil Janssen Pharm Novedosos compuestos heterociclicos biciclicos sustituidos como moduladores de la gamma secretasa.
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
TW201035101A (en) 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
EP2403835A1 (en) 2009-03-03 2012-01-11 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
US20110299830A1 (en) 2009-03-16 2011-12-08 Panasonic Corporation Application running device
EP2414340A1 (en) * 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
JP2012525390A (ja) * 2009-04-27 2012-10-22 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換イミダゾ［１，２−ａ］ピリジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法
JP5559309B2 (ja) 2009-05-07 2014-07-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体
JP2010274429A (ja) 2009-05-26 2010-12-09 Ihi Corp アライメントステージ
SG177644A1 (en) 2009-07-15 2012-03-29 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
US9079886B2 (en) 2010-01-15 2015-07-14 Janssen Pharmaceuticals, Inc. Substituted triazole derivatives as gamma secretase modulators
US8569331B2 (en) * 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds
US8987276B2 (en) 2011-03-24 2015-03-24 Janssen Pharmaceuticals, Inc. Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物

Also Published As

Publication number Publication date
TWI567079B (zh) 2017-01-21
AR087182A1 (es) 2014-02-26
CA2841102C (en) 2019-08-13
NZ619683A (en) 2015-01-30
TW201315736A (zh) 2013-04-16
EA201490287A1 (ru) 2014-05-30
CA2841102A1 (en) 2013-01-24
AU2012285931B2 (en) 2017-01-12
US9115143B2 (en) 2015-08-25
EP2731948A1 (en) 2014-05-21
EA023045B1 (ru) 2016-04-29
ES2555167T3 (es) 2015-12-29
EP2731948B1 (en) 2015-09-09
WO2013010904A1 (en) 2013-01-24
IN2014MN00258A (pt) 2015-09-25
CN103874702B (zh) 2015-12-09
KR20140063595A (ko) 2014-05-27
IL230422B (en) 2018-03-29
KR101913135B1 (ko) 2018-10-30
JP6068464B2 (ja) 2017-01-25
CN103874702A (zh) 2014-06-18
US20140148450A1 (en) 2014-05-29
MX2014000626A (es) 2014-04-30
JP2014518286A (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
BR112014000713A2 (pt) derivados de indol substituído como moduladores de gama secretase
BRPI1008473A2 (pt) compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
BR112013023984A2 (pt) derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase
BR112012017442A2 (pt) derivados de triazol bicíclicos substituídos como moduladores de gamma secretase
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
BR112015010908A2 (pt) derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
BRPI1011190A8 (pt) Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
EA201171066A1 (ru) Новые замещенные производные бензоксазола, бензимидазола, оксазолопиридина и имидазопиридина в качестве модуляторов гамма-секретазы
BR112014033080A2 (pt) inibidores do vírus da hepatite c
BR112012017580A2 (pt) derivados de heteroarila contendo nitrogênio
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BR112012012259A2 (pt) compostos como moduladores de receptor com utilidade terapêutica
BR112012009310B8 (pt) composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos
BRPI0817223B8 (pt) inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
BR112015024971A2 (pt) derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
BR112014004522A2 (pt) moduladores de pde10
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time